Neuroendocrinology. 2018;106(3):264-273. doi: 10.1159/000480015. Epub 2017 Aug 17.
The natural history and the best modality of follow-up of atypical lung carcinoids (AC) remain ill defined. The aim of this study was to analyze recurrence-free survival (RFS) after complete resection (R0) of stage I-III pulmonary AC. Secondary objectives were prognostic parameters, the location of recurrences, and the modality of follow-up.
A retrospective review of 540 charts of AC patients treated between 1998 and 2008 at 10 French and Italian centers with experience in lung neuroendocrine tumor management was undertaken. The exclusion criteria were MEN1-related tumor, history of another cancer, referral after tumor relapse, and being lost to follow-up. A central pathological review was performed in each country.
Sixty-two patients were included. After a median follow-up time of 91 months (mean 85, range 6-165), 35% of the patients experienced recurrence: 16% were regional recurrences and 19% were distant metastases. Median RFS was not reached. The 1-, 3-, and 5-year RFS rate was 90, 79, and 68%, respectively. In univariate analysis, lymph node involvement (p = 0.0001), stage (p = 0.0001), mitotic count (p = 0.004), and type of surgery (p = 0.043) were significantly associated with RFS. In multivariate analysis, lymph node involvement was significantly associated with RFS (HR 95% CI: 0.000-0.151; p = 0.004). During follow-up, somatostatin receptor scintigraphy, fibroscopy, and abdominal examination results were available for 22, 12, and 25 patients, respectively. The median time interval for imaging follow-up was 10 months.
After complete resection of AC, recurrences were observed mostly within the first 5 years of follow-up, within bronchi, mediastinal nodes, the liver, and bones. In R0 patients, lymph node involvement could help to stratify follow-up intervals. Suboptimal imaging is evidenced.
不典型肺类癌(AC)的自然史和最佳随访方式仍不明确。本研究旨在分析 I-III 期肺 AC 完全切除(R0)后的无复发生存率(RFS)。次要目标是分析预后参数、复发部位和随访方式。
回顾性分析了 1998 年至 2008 年间,10 家法国和意大利中心的 540 例 AC 患者的病历,这些中心在肺神经内分泌肿瘤的管理方面经验丰富。排除标准为 MEN1 相关肿瘤、其他癌症病史、肿瘤复发后转诊和随访丢失。每个国家都进行了中央病理复查。
共纳入 62 例患者。中位随访时间为 91 个月(平均 85 个月,范围 6-165 个月),35%的患者出现复发:16%为局部复发,19%为远处转移。中位 RFS 未达到。1、3 和 5 年 RFS 率分别为 90%、79%和 68%。单因素分析显示,淋巴结受累(p = 0.0001)、分期(p = 0.0001)、有丝分裂计数(p = 0.004)和手术类型(p = 0.043)与 RFS 显著相关。多因素分析显示,淋巴结受累与 RFS 显著相关(HR 95%CI:0.000-0.151;p = 0.004)。在随访期间,22、12 和 25 例患者分别可获得生长抑素受体闪烁扫描、纤维镜和腹部检查结果。影像学随访的中位时间间隔为 10 个月。
在 AC 完全切除后,复发主要发生在随访的前 5 年内,发生部位为支气管、纵隔淋巴结、肝脏和骨骼。在 R0 患者中,淋巴结受累有助于分层随访间隔。影像学检查并不理想。